0001209191-18-060062.txt : 20181127
0001209191-18-060062.hdr.sgml : 20181127
20181127192108
ACCESSION NUMBER: 0001209191-18-060062
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181126
FILED AS OF DATE: 20181127
DATE AS OF CHANGE: 20181127
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smith David V
CENTRAL INDEX KEY: 0001229447
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36070
FILM NUMBER: 181203953
MAIL ADDRESS:
STREET 1: 6035 STONERIDGE DRIVE
CITY: PLEASANTON
STATE: CA
ZIP: 94588
FORMER NAME:
FORMER CONFORMED NAME: SMITH DAVID V
DATE OF NAME CHANGE: 20030429
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: FIVE PRIME THERAPEUTICS INC
CENTRAL INDEX KEY: 0001175505
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 260038620
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 111 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-365-5600
MAIL ADDRESS:
STREET 1: 111 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-11-26
0
0001175505
FIVE PRIME THERAPEUTICS INC
FPRX
0001229447
Smith David V
111 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Executive Vice President & CFO
Common Stock
2018-11-26
4
A
0
40000
0.00
A
40000
D
Employee Stock Option (right to buy)
12.47
2018-11-26
4
A
0
185000
0.00
A
2028-11-25
Common Stock
185000
185000
D
Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of November 26, 2019, 2020 and 2021, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the "Company") through each such date.
One fourth (1/4) of the shares underlying this option will vest on November 26, 2019, and the remainder of the shares underlying this option will vest at a rate of one forty-eighth (1/48) per month thereafter, provided the reporting person provides services to the Company through each such date.
/s/ Francis Sarena, Attorney-in-fact
2018-11-27